Classified in: Health

Woven Health Collective Unveils Groundbreaking Advocacy-Led Consensus to Improve Diagnosis and Care Experiences for High-Risk Neuroblastoma Patients at ANR 2025

, /PRNewswire-PRWeb/ -- Woven Health Collective announced the presentation of a first-of-its-kind advocacy-led consensus poster at the Advances in Neuroblastoma Research (ANR) Meeting, May 25?28, 2025, in Washington, D.C. Developed in close collaboration with a dedicated Advocacy Advisory Council and supported by Y-mAbs Therapeutics, Inc., this initiative establishes a shared framework to improve the diagnostic and care experience for patients and families facing high-risk neuroblastoma (HR NB).

This foundational work lays the groundwork for the development of hospital resources, provider training, and caregiver education tools?part of Woven Health's commitment to transforming science into meaningful, patient-centered solutions.

"As parent advocates, we've long seen the need for a unified approach to diagnosis and early care, one that prioritizes clear communication, emotional support, and shared decision-making from the start and throughout the care journey," said Vickie Buenger, President Emeritus of the Coalition Against Childhood Cancer (CAC2).

The poster, Bridging the Gap: Establishing Consensus for Improving High-Risk Neuroblastoma Diagnosis and Care Experiences for Patients and Caregivers, reflects the collective insights of leading neuroblastoma advocates and aims to address longstanding gaps, at diagnosis and throughout care.

"This consensus effort is a vital reminder that how we deliver care is just as important as what care we deliver," said Maggie Fader, MD, Pediatric Hematologist/Oncologist at Nicklaus Children's Hospital. "By incorporating the lived experiences of patients and families, we're better equipped to provide compassionate, transparent, and truly patient-centered care, especially at the most critical and vulnerable moment."

Initial consensus statements spanned six key domains: Critical Encounters, Unmet Educational Needs, Treatment Goals and Management Plans, Ethics, Health Equity, and Patient/Provider Communication. Statements emphasized the importance of transparency in early provider interactions, alignment with family-defined treatment goals, and systemic support for equitable care access. All consensus items achieved high agreement (?4.1 points), underscoring the broad relevance and urgency of these needs.

"At Woven, we believe in the importance of empowering patients, caregivers, and advocates with the knowledge and tools they need to engage in transparent, shared decision-making with healthcare providers," said Jeff Stumpf, PhD, CMPP, Executive Vice President at Woven Health Collective. "We were proud to facilitate this consensus program and play a role in bridging educational gaps and establishing best practices in neuroblastoma care."

This foundational work lays the groundwork for the development of hospital resources, provider training, and caregiver education tools?part of Woven Health's commitment to transforming science into meaningful, patient-centered solutions.

About Woven Health Collective:

Woven Health Collective is an integrated biopharmaceutical marketing, strategy, and scientific communications company that partners with clients to translate complex science into powerful stories that drive impact. With a unified approach, deep scientific expertise, and cutting-edge technology, Woven delivers novel, client-centric solutions across the entire product lifecycle?from development and launch to commercialization and market expansion. The collective is distributed across North America and Europe, with central offices in New York, Montreal, Raleigh, and Atlanta.

�

Woven Media Contact:

Vin Keane, VP, Marketing

[email protected]

�

About Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company's technologies include its investigational Self-Assembly DisAssembly ("SADA") Pretargeted Radioimmunotherapy Platform ("PRIT") and bispecific antibodies generated using the Y-BiClone platform. The Company's broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA� (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2025 and beyond. Words such as ''anticipate,'' ''believe,'' "contemplate," ''continue,'' ''could,'' ''estimate,'' ''expect,'' "hope," ''intend,'' ''may,'' ''might,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''should,'' ''target,'' "will," ''would',' "guidance," "goal," "objective," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's business is subject to risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the Company's Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2025, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

SADA�, SADA PRITtm, DANYELZA� and Y-mAbs� are registered trademarks of Y-mAbs Therapeutics, Inc.

Y-mAbs Investor Contact:

Courtney Dugan

VP, Head of Investor Relations

[email protected]

�

Y-mAbs Patient Advocacy Contact:

Marcie Reeder

Director, Patient Advocacy and Communications

[email protected]

Media Contact

Vincent Keane, Woven Health Collective, 1 6469795444 3450, [email protected], https://www.wovenhc.com�

Courtney Dugan, Y-mAbs Investor Contact, [email protected], https://ymabs.com�

SOURCE Woven Health Collective

News published on 27 may 2025 at 11:30 and distributed by: